Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1

Status

Completed 19Recruiting 8Terminated 4Active not recruiting 3Withdrawn 2Unknown 2Not yet recruiting 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 2Thoracic 1Head & Neck 1CNS 1Breast 1

Conditions

Carcinoma, Non-Small-Cell Lung 16Breast Neoplasms 14Prostatic Neoplasms 11Neoplasm Metastasis 7Lung Neoplasms 4Squamous Cell Carcinoma of Head and Neck 3Sarcoma 3Salivary Gland Neoplasms 3Histiocytoma, Malignant Fibrous 3Head and Neck Neoplasms 3Dermatofibrosarcoma 3Bone Neoplasms 3Urinary Bladder Neoplasms 2Solid Tumors 2Small Cell Lung Carcinoma 2Sarcoma, Synovial 2Rhabdomyosarcoma 2Neoplasms 2Liposarcoma 2Leiomyosarcoma 2Hemangiosarcoma 2Esthesioneuroblastoma, Olfactory 2Carcinoma, Transitional Cell 2Uterine Cervical Neoplasms 1Thyroid Neoplasms 1Thyroid Carcinoma, Anaplastic 1Thyroid Cancer, Papillary 1Recurrent Squamous Cell Lung Carcinoma 1Pathologic Complete Response 1Ovarian Neoplasms 1

Interventions

tremelimumab 4Cystoscopy 3durvalumab 2avelumab 2Paclitaxel 2Gemcitabine 2Docetaxel 2Cisplatin 2vocimagene amiretrorepvec 1vinflunine 1trebananib 1trastuzumab duocarmazine 1pegfilgrastim 1merphos 1infigratinib 1erdafitinib 1efineptakin alfa 1copanlisib 1atezolizumab 1Vinblastine 1Trastuzumab 1Taxes 1TAS-116 1Specimen Handling 1Sirolimus 1Rosiglitazone 1Ropivacaine 1Rogaratinib 1Radiotherapy 1Polymerase Chain Reaction 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Withdrawn × Urinary Bladder Neoplasms × Docetaxel × Clear all
NCT00041171 2016-07-12

Docetaxel and St. John's Wort in Treating Patients With Solid Tumors That Cannot Be Removed By Surgery

Alliance for Clinical Trials in Oncology

Phase 3 Withdrawn
BreastCNSGenitourinaryHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Urinary Bladder Neoplasms, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Head and Neck Neoplasms, Prostatic Neoplasms, Salivary Gland Neoplasms, Esthesioneuroblastoma, Olfactory, Small Cell Lung Carcinoma

NCT01907308 2014-04-29

Trebananib (AMG 386) in Combination With Docetaxel for Advanced Urothelial Carcinoma

University of Colorado, Denver

Phase 2 Withdrawn
Genitourinary

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡